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Abstract
Background: Pulmonary carcinoid tumors make up approximately one percent of all pulmonary tumors, and
controversy exists regarding management and prognosis. We undertook a retrospective analysis of all patients
who underwent surgical resection of pulmonary carcinoid tumors at our institution.
Methods: From 1992 through 2014, 121 patients who underwent surgical resection of pulmonary carcinoid tumors
were retrospectively reviewed. Patient demographics, pathologic data and long-term outcomes were recorded.
Results: There were 96 patients with typical carcinoid tumors and 25 patients with atypical carcinoid tumors.
All patients received complete resection of their tumors, with 90 % (109/121) of patients undergoing anatomic
resection. There were no peri-operative mortalities. Eighty-one percent (98/121) of patients were female. Mean
age was 60.7 years. Five and ten year survival rates were 96 % and 88 % respectively for typical carcinoid tumors,
as compared to 87 % and 69 % respectively for atypical carcinoid tumors. Tumor size was not associated with
survival (p = 0.98). Nodal metastases were evident in 8 % (8/96) of typical carcinoid tumors and 28 % (7/25) percent of
atypical carcinoid tumors. Among typical carcinoid cases, the presence of nodal metastases were not associated with
overall survival (p = 0.55). Among atypical carcinoid cases, the presence of nodal metastases also was not associated
with survival (p = 0.53). No patients received neoadjuvant or adjuvant chemoradiation treatment.
Conclusions: Excellent long-term outcomes can be achieved following surgical resection of pulmonary carcinoid
tumors. The presence of nodal metastases was not associated with overall survival. Tumor size was not associated with
either recurrence rates or survival.
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Background
Pulmonary carcinoid tumors make up approximately 1–
2 % of all pulmonary tumors [1]. They are derived from
the Kulchitsky cell and generally have indolent growth
patterns. Carcinoid tumors are categorized as typical or
atypical, based on number of mitoses per high power
field and presence of necrosis [2]. Surgical resection is
the standard treatment for pulmonary carcinoid tumors
[3]. There exists debate, however, about the use of
adjuvant treatment in patients with locoregional metas-
tases or patients with atypical tumors [4, 5]. We under-
took a retrospective review to determine the outcomes
of patients with pulmonary carcinoid tumors who
underwent surgical resection.
Methods
After approval by the institutional review board, a data-
base search for pulmonary carcinoid tumors was per-
formed from pathology records of two Brown University
hospitals (The Rhode Island Hospital and The Miriam
Hospital) over a 22 year period (1992–2014). Over this
time span, 121 patients with pulmonary carcinoid tu-
mors underwent surgical resection. Patients who were
incidentally found to have a carcinoid tumorlet as part
of their resection specimen were not included in the
study. Pathologic confirmation of carcinoid tumor was
established by a pathologist in all cases. Tumors were
classified as typical carcinoid if there were less than 2
mitoses per 2 square millimeters (mm2) and no necrosis.
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Table 2 Pathologic results
Typical histology 79 % (96/121)
Anatomic resection 89 % (108/121)
Size, cm (mean) 2.3 ± 1.4
Stage I 85 % (103/121)
II 7 % (8/121)
III 8 % (10/121)
Table 3 Typical vs. atypical histology
Typical Atypical p-value
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2 and 10 mitoses per mm2 or evidence of necrosis. Pa-
tient demographics, use of chemotherapy or radiation,
peri-operative variables, type of surgical resection, recur-
rence rates and survival were analyzed retrospectively.
Anatomic resection consisted of either segmentectomy,
lobectomy, bi-lobectomy or pneumonectomy. Follow-up
status was obtained from institutional records and veri-
fied by the national social security database.
The Mann–Whitney test was used to compare differ-
ences in continuous variables between different tumor
groups. Fisher’s exact and Chi-squared tests were used
to compare categorical variables. Univariate survival
analysis was performed using Kaplan-Meier curves com-
pared with log rank or Cox regression analysis. Multi-
variate survival analysis was performed with Cox
regression analysis, using variables with a p-value of less
than 0.1 on univariate analysis.
Results
Patients
A list of patient demographics is shown in Table 1.
Eighty-one percent (98/121) of the patients were female.
Mean age was 60.7 years (11–81). Mean follow-up time
was 70.2 months (1–259).
Surgical management
Anatomic resection was performed in 89 % (108/121) of
patients. All patients had complete resection of their
tumor. Eleven percent (13/121) of patients underwent
resection using a minimally invasive, video-assisted ap-
proach. There were no peri-operative mortalities. Mean
length of stay was 4.9 days.
Pathologic analysis
Pathologic results are shown in Table 2. Mean size was 2.3
centimeters (cms). Twenty-one percent (25/121) of pa-
tients had an atypical carcinoid tumor. Nodal metastases
were present in 8 % (8/96) of patients with typical carcin-
oid tumors and 28 % (7/25) of patients with atypical car-
cinoid tumors (p < 0.01, Table 3). Patients with atypical
carcinoid tumors had greater tumor size than patients
with typical carcinoid tumors (2.0 cm vs. 3.2 cm, p < .01).
Patients with atypical carcinoid tumors were also more
likely to have increased number of lymph node metastasesTable 1 Demographics
N 121
Age (Mean) 60.7 ± 13.5
Female 81 % (98/121)
Diabetes mellitus 16 % (19/121)
Cardiac disease 12 % (14/121)
Follow-up, months (mean) 70.2 (1–259)than patients with typical carcinoid tumors (p < 0.01). In
patients with atypical carcinoid tumors, the mean number
of mitoses per high power field was 3.9.
Chemoradiation
No patient received neoadjuvant chemotherapy or radi-
ation treatment. Similarly, no patient received adjuvant
treatment in the early postoperative period. All patients
who experienced recurrent disease received chemother-
apy and/or radiation treatment. The usual chemother-
apy regimen consisted of cisplatin-based treatment.
The decision to use chemotherapy and/or radiation
therapy was individualized in each of these patients and
based on extent and location of recurrence and pres-
ence of symptoms.
Disease-free survival and overall survival
At the time of last follow-up, 88 % (107/121) of patients
were alive in the overall cohort. Five and ten year sur-
vival overall were 93 % and 84 % respectively. Of the
patients with typical carcinoid tumor, 89 % (85/96) were
alive without disease, 1 % (1/96) was alive with distant
recurrent disease, and 10 % (10/96) had died without
disease. Five and ten year survival in patients with typ-
ical carcinoid were 96 % and 88 % respectively.
Of the patients with atypical carcinoid tumor, 76 %
(19/25) were alive without disease, 8 % (2/25) were alive
with distant recurrent disease, 12 % (3/25) died with
disease, and 4 % (1/25) died without disease. Two of the
3 patients who died with disease had distant recurrent
disease, while the other patient had both distant and
local recurrences. Five and ten year survival in patients
with atypical carcinoid were 87 % and 69 % respectively.(N = 96) (N = 25)
Age, years (mean) 60.0 ± 13.2 63.3 ± 9.8 0.24
Tumor size, cm (mean) 2.0 ± 1.3 3.2 ± 2.2 <0.01
Positive lymph node status 8 % (8/96) 28 % (7/25) <0.01
Number of lymph node metastases 0.1 0.6 <0.01
Disease-free survival 0.02
Overall survival 0.09
Bold values indicate statistically significant results
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creasing age (p = 0.03) and atypical histology (p = 0.02,
Fig. 1). Disease-free survival was not associated with
anatomic resection (p = 0.91), size (p = 0.11), positive
lymph node status (p = 0.44) or number of lymph node
metastases (p = 0.13).
Using univariate analysis, factors which were associ-
ated with overall survival were age (p = 0.03) and num-
ber of mitoses (p < 0.01). Overall survival was not
affected, however, by typical/atypical histology (p = 0.09),
positive lymph node status (p = 0.55) or anatomic resec-
tion (p = 0.78). When multivariate analysis was used, in-
cluding all variables with a p value less than .1, only the
number of mitoses was significantly associated with sur-
vival (p = 0.04).
Discussion
Overall survival for pulmonary carcinoid tumors is ex-
cellent, and surgical resection remains the standard of
care for these tumors [6]. There exist many different
standards and practices for surgical management,
however [7]. All of our patients underwent complete
resection of their tumor. In our analysis both overall
survival and disease-free survival were not affected by
undergoing an anatomic resection. But in our study the

























Fig. 1 Relationship between typical/atypical histology and disease-free
worsened disease-free survivalresection performed, and conclusions concerning ana-
tomic resection vs. limited resection are difficult. We
feel that an anatomic resection should be favored for
carcinoid tumors, and limited resections should be
considered only for patients who lack sufficient pul-
monary reserve.
Similarly, presence or number of lymph node metasta-
ses did not affect survival in our study. But given the
relatively small number of patients in our study with
nodal involvement, caution should be taken in determin-
ing the prognostic impact of nodal status. And other
studies have shown that nodal involvement does have an
impact on outcome of patients with carcinoid tumors
[8]. It does seem, however, that patients can live for ex-
tended periods of time with microscopic disease, given
the indolent nature of carcinoid tumors. Our surgical
practice has been to perform a hilar and mediastinal
lymph node dissection similar to what we perform for
patients with non-small cell lung cancer.
Atypical carcinoid tumors do appear to have more
aggressive biology, with statistically increased tumor size
and propensity for lymph node metastases [9–12]. And
while patients with atypical carcinoid tumors were more
likely to develop recurrent disease, overall survival was
not affected by typical/atypical histology. This trend




survival. Patients with atypical histology experienced a significantly
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out significant symptomatology or complications [13, 14].
Though it appears that patients with atypical carcinoid
tumors are more likely to recur, they can live with disease
without considerable morbidity for prolonged periods.
Given the long time frame of the study, preoperative
staging and postoperative surveillance strategy varied
widely among the cohort [15]. In the early part of this
study computed tomography (CT) scan only was used to
stage the patient. Now we obtain positron emission tom-
ography – computed tomography (PET-CT) scans dur-
ing the preoperative workup of our patients. Our
current postoperative surveillance strategy has been to
perform CT scan evaluation every 6 months for the first
2 years, and then yearly thereafter until year 5. After
that, CT scan is performed only if there is suspicion of
recurrence based on symptomatology or clinical find-
ings. In our study, only 1 patient recurred after 5 years
from resection. That patient is currently alive with dis-
ease but no symptoms.
There exist multiple different practice patterns re-
garding the use of chemotherapy to treat pulmonary
carcinoid tumors [16–19]. Chemotherapy is generally
not recommended to treat a patient with typical
carcinoid tumors who recurs, as typical carcinoid tu-
mors are generally less responsive to chemotherapy
[20]. The 1 patient in our study with typical carcinoid
who recurred was, as such, treated with radiation
therapy only. Patients with atypical carcinoid tumors
who recur may experience a survival benefit with
chemotherapy.
Along with the retrospective nature of the series, our
study is limited by other factors. The overall number of
patients in the series is relatively low, but the overall and
disease-free survival rates were similar compared to
other studies. And because disease recurrences were so
infrequent, even in patients with atypical carcinoid tu-
mors, it was difficult to determine a group of patients
with a recurrence risk great enough to warrant chemora-
diation therapy. A larger multi-center study would po-
tentially identify patients who would benefit from
adjuvant treatment, such as a patient with an atypical
carcinoid tumor with a very high number of mitoses.Conclusions
Patients with pulmonary carcinoid tumors can experi-
ence excellent long term outcomes following complete
resection of their tumors. Presence of lymph node me-
tastases and tumor size do not appear to affect recur-
rence rates or survival. Further multi-center studies
may potentially identify a high-risk cohort that would
benefit from neoadjuvant or adjuvant chemotherapy or
radiation treatment.Competing interests
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